TIMD4 T cell immunoglobulin and mucin domain containing 4
ENSG00000145850 · protein coding · Open Targets profile
Phosphatidylserine receptor that plays different role in immune response including phagocytosis of apoptotic cells and T-cell regulation (PubMed:18082433, PubMed:32640697). Involved in efferocytosis, the process by which apoptotic cells are removed by phagocytic cells by promoting the engulfment of apoptotic cells or exogenous particles (PubMed:18082433, PubMed:32703939, PubMed:34067457). Mechanistically, acts by securing apoptotic cells to phagocytes through direct binding to phosphatidylserine present on apoptotic cells, while other engulfment receptors such as MERTK efficiently recognize apoptotic cells and mediate their ingestion (PubMed:32640697). Controls T-cell activation in a bimodal fashion, decreasing the activation of naive T-cells by inducing cell cycle arrest, while increasing proliferation of activated T-cells by activating AKT1 and ERK1/2 phosphorylations and subsequent signaling pathways (By similarity). Also promotes autophagy process by suppressing NLRP3 inflammasome activity via activation of LKB1/PRKAA1 pathway in a phosphatidylserine-dependent mechanism (By similarity). {ECO:0000250|UniProtKB:Q6U7R4, ECO:0000269|PubMed:18082433, ECO:0000269|PubMed:32640697, ECO:0000269|PubMed:32703939, ECO:0000269|PubMed:34067457}.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- UniProt loc high conf, UniProt SigP or TMHMM, GO CC med conf, Human Protein Atlas loc
gnomAD loss of function constraint: o/e 0.7520700097084045 (upper bound 1.0149999856948853). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
No named investigators on registry trials of TIMD4's approved or late-stage drugs in the last three years.
No terminated, withdrawn or suspended trials of TIMD4's drugs are registered
All 0 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| No drugs or clinical candidates recorded. | ||||